VLC
CELG

Van Leeuwen & Company’s Celgene Corp CELG Stock Holding History

Van Leeuwen & Company’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-10,105
Closed -$648K – 86
2018
Q4 		$648K Sell
10,105
-230
-2% -$17K 0.65% 48
2018
Q3 		$925K Buy
+10,335
New +$913K 0.85% 41

Other funds holding CELG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Van Leeuwen & Company's CELG Position: Q1 2019 in Review

Van Leeuwen & Company sold out of Celgene Corp (CELG) in Q1 2019, closing a stake of 10,105 shares — an estimated $648K sold.

Van Leeuwen & Company first reported a position in CELG in Q3 2018 and held it in 2 quarters. The position peaked at $925K in Q3 2018. 1,389 funds tracked by Wall St. Rank hold CELG as of Q1 2019.

  • Van Leeuwen & Company reported no remaining Celgene Corp position as of Q1 2019 after selling out during the quarter.
  • Van Leeuwen & Company sold 10,105 Celgene Corp shares in Q1 2019, an estimated $648K.
  • Van Leeuwen & Company first reported a position in Celgene Corp in Q3 2018 and held it in 2 quarters.
  • Van Leeuwen & Company's Celgene Corp position peaked at $925K in Q3 2018.
  • 1,389 funds tracked by Wall St. Rank held Celgene Corp as of Q1 2019.

Based on Van Leeuwen & Company's 13F filing for Q1 2019, filed 15 May 2019.